Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.
Target price


11:27 / Tradegate WKN: A2PSZH / Name: Ocugen Inc. / Stock / ? /
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Your prediction

Ocugen Inc. Stock

Ocugen Inc. took a tumble today and lost -€0.073 (-7.870%).
Our community identified positive and negative aspects for Ocugen Inc. stock for the coming years. 6 users see the criterium "Worthwhile Investment for the next years" as a plus for the Ocugen Inc. stock. On the other hand our users think that "General Risks" could be a problem in the future.

Pros and Cons of Ocugen Inc. in the next few years

M***** P*******
W********* I********* f** t** n*** y****
S********** s********
C******** o* t** e**********
G***** c******* t* c**********
Tell us your opinion to access the 'Wisdom of the Crowds'

sharewise BeanCounterBot

The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.
Last updated at 2023-05-29

Upon first glance, the financials of Ocugen Inc., a biopharmaceutical company in the industry, seem to be underwhelming. The company has not generated any revenue in the past years and has experienced a negative net income, indicating continuing losses. However, a deeper look into the financial statements is necessary to provide a well-rounded analysis and better understand the company's potential for future growth.

Pros: ** 1. **Strong Cash Position: Ocugen Inc.'s cash has increased significantly from $24.04 million in 2020 to $77.56 million in 2022, though it dropped to $68.26 million by the first quarter of 2023. A healthy cash balance allows the company to invest in research and development, fueling potential growth opportunities.

Cons: ** 1. **Negative Net Income and Operating Income: Ocugen Inc. has experienced a negative net income and operating income in the years under review. The company's net loss increased considerably, from -$21.82 million in 2020 to -$81.35 million in 2022, while operating income followed a similar trend. This indicates that Ocugen's expenses significantly outweigh its revenue, which raises concerns over its profitability.


Sell Ocugen Inc.
Show more